Anticoagulant therapy beyond primary treatment among active cancer and non-cancer patients with venous thromboembolism in the United States

Back

ESC Professional Premium Access

Anticoagulant therapy beyond primary treatment among active cancer and non-cancer patients with venous thromboembolism in the United States

Session: Oral anticoagulation in patients with venous thromboembolism or left ventricular thrombus

Topic: Anticoagulants

Speaker: Doctor A. Cohen (London, GB)

Event: ESC Congress 2023

Congress Presentation

About the speaker

Doctor Alexander Thomas Cohen

Guy's and St Thomas' NHS Trust Hospitals, London (United Kingdom of Great Britain & Northern Ireland)

13 presentations

0 follower

6 more presentations in this session

Baseline characteristics and outcomes of extended oral anticoagulant treatment in patients with venous thrombosis: a retrospective cohort study in France

Speaker: Mr R. Subash (Surrey, GB)

Comparative effectiveness and safety of apixaban and low-molecular weight heparin among patients with venous thromboembolism and active cancer in an extended treatment setting

Speaker: Doctor A. Cohen (London, GB)

The effect of DOAC-Stop on lupus anticoagulant testing in patients with pulmonary embolism receiving direct oral anticoagulants

Speaker: Professor A. Undas (Krakow, PL)

Clinical characteristics and outcomes of super-low-dose edoxaban of 15 mg in patients with acute venous thromboembolism: insight from the COMMAND VTE Registry-2

Speaker: Doctor K. Kaneda (Kyoto, JP)

Predicting thrombus outcome during anticoagulation for left ventricular thrombus

Speaker: Doctor Q. Yang (Beijing, CN)

Access

Abstract

Slides

Access the full session

Oral anticoagulation in patients with venous thromboembolism or left ventricular thrombus

Speakers: Doctor A. Cohen, Mr R. Subash, Doctor A. Cohen, Professor A. Undas, Doctor K. Kaneda...

Access

About the event

ESC Congress 2023

25 August - 28 August 2023

Sessions Presentations

Congress

Anticoagulant therapy beyond primary treatment among active cancer and non-cancer patients with venous thromboembolism in the United States

About the speaker

Doctor Alexander Thomas Cohen

6 more presentations in this session

Baseline characteristics and outcomes of extended oral anticoagulant treatment in patients with venous thrombosis: a retrospective cohort study in France

Comparative effectiveness and safety of apixaban and low-molecular weight heparin among patients with venous thromboembolism and active cancer in an extended treatment setting

The effect of DOAC-Stop on lupus anticoagulant testing in patients with pulmonary embolism receiving direct oral anticoagulants

Clinical characteristics and outcomes of super-low-dose edoxaban of 15 mg in patients with acute venous thromboembolism: insight from the COMMAND VTE Registry-2

Predicting thrombus outcome during anticoagulation for left ventricular thrombus

Access the full session

Oral anticoagulation in patients with venous thromboembolism or left ventricular thrombus

About the event

ESC Congress 2023

ESC 365 is supported by